ClinicalTrials.gg
Not yet recruitingNCT07090954Updated Jul 29, 2025

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

A Phase 1/2 interventional study of GR1803 injection and Anti-CD38 Monoclonal Antibody in Multiple Myeloma, sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd. (part of Chongqing Genrix Biopharmaceutical Co., Ltd) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
223rd of 406
32 · median 40
Started
2025
with 54 others
Phase 1/2
65 of 448
43 open now
Primary completion
2026-07
later than 92 of 274 live
Registered
364th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 223rd largest by planned enrollment of the 406 interventional ones that give a count, is one of 55 that started in 2025, is one of 65 in phase 1/2, reaches primary completion later than 92 of the 274 other live ones, and was the 364th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status grade of 0, 1 or 2;
  • Diagnosis of multiple myeloma;have received at least one including Lenalidomide and a proteasome inhibitor.
  • Able to understand and comply with the requirements of the clinical protocol, voluntarily participate in the clinical trial, and sign .

Exclusion criteria

Exclusion Criteria:

  • Plasma cell leukemia , Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis.
  • Active central nervous system involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
  • Prior treatment with any BCMA-targeted therapiy.
  • Active infecion.
  • Known allergies, , or intolerance to the study drug or its .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    GR1803 plus anti-CD38 monoclonal antibody

    Participants will be assigned to a combination of anti-CD38 monocloncal antibody plus GR1803 injection.

    Drug: GR1803 injection · Drug: Anti-CD38 Monoclonal Antibody

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Number of Participants With Dose Limiting Toxicity (DLT)

    The dose limiting toxicities are defined as any of the following events: drug related hematological or non-hematological toxicity of grade 3 or higher.

    Time frame: Up to 2 Years

  2. Dose escalation: Number of Participants With Adverse Events and Serious Adverse Events

    Adverse event is any untoward medical occurrence in a clinical trial participants administered a pharmaceutical product, regardless of causal relationship to the study treatment. This includes any unfavorable or unintended sign, symptom, or disease temporally associated with the use of the product. Serious adverse event is an adverse event that results in any of the following outcomes: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, other medically important events.

    Time frame: Up to 2 Years

  3. Dose expansion: Overall Response Rate

    The percentage of participants who have a partial response or better according to the International Myeloma Working Group criteria

    Time frame: Up to 2 Years

Secondary outcomes

  1. Duration of Response

    Time from initial partial response or better to progressive disease or death due to any cause

    Time frame: Up to 2 Years

  2. Progression-Free Survival

    Time from first administration of GR1803 injection to tumor progerssion or death from any cause

    Time frame: Up to 2 Years

  3. Serum Concentration of GR1803 Injection

    Serum concentration of GR1803 injection will be assessed

    Time frame: Up to 2 Years

  4. Number of Participants With Anti-Drug Antibodies to GR1803 Injection

    Number of participants with anti-drug antibodies to GR1803 injection will be assessed

    Time frame: Up to 2 Years

07

Study locations

2 sites
  • Shanghai Fourth People's Hospital Affiliated with Tongji University
    Shanghai, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Jul 2026, 11 months later.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 11 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Jul 29, 2025
StartEst.
Aug 31, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jan 31, 2030
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07090954
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Aug 31, 2025 (estimated)
Primary completion
Jul 31, 2026 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Jul 29, 2025

Study contacts

Cheng P He, Doctor of Meicine
Contact
hepc_gcp@163.com
86+18991232609

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GR1803 · Anti-CD38 Monoclonal Antibody

Start the discussion